Research progression of gut microbiota and its metabolites in colorectal cancer

doi:10.3877/cma.j.issn.2095-3224.2017.05.015

Abstract

Abstract:

Understanding of intestinal micro-ecological and metabolic changes, identification of reliable markers of early colorectal cancer screening and early diagnosis is essential. Recent studies have found that gut microbiota and its metabolites formed a variety of complex intestinal ecological environment which profoundly affect the intestinal stability and disease state. This review focuses on the study of gut microbiota and its metabolites in colorectal cancer patients, and reviews the recent progress of then for the early diagnosis of cancer.

Key words: Colorectal neoplasms, Metabolism, Gut microbiota, Study progress

Cheng Kong, Renyuan Gao, Linsheng Huang, Peng Zhang, Huanlong Qin. Research progression of gut microbiota and its metabolites in colorectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2017, 06(05): 421-426.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2017.05.015

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2017/V06/I05/421

Figures/Tables 1

References 53

[1]	Svensson T, Yamaji T, Budhathoki S, et al. Alcohol consumption, genetic variants in the alcohol- and folate metabolic pathways and colorectal cancer risk: the JPHC Study[J]. Sci Rep, 2016, 6:36607.
[2]	Tuan J, Chen YX. Dietary and Lifestyle Factors Associated with Colorectal Cancer Risk and Interactions with Microbiota: Fiber, Red or Processed Meat and Alcoholic Drinks[J]. Gastrointest Tumors, 2016, 3(1):17-24.
[3]	Yang C, Wang X, Huang CH, et al. Passive Smoking and Risk of Colorectal Cancer: A Meta-analysis of Observational Studies[J]. Asia Pac J Public Health, 2016, 28(5):394-403.
[4]	Goss PE, Strasser-Weippl K, Lee-Bychkovsky BL, et al.Challenges to effective cancer control in China, India, and Russia[J]. Lancet Oncol, 2014, 15(5):489-538.
[5]	Varghese C and Shin HR, Strengthening cancer control in China[J]. Lancet Oncol, 2014, 15(5):484-485.
[6]	Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis[J]. Nat Rev Cancer, 2007, 7(8):599-612.
[7]	Halsted CH, Villanueva JA, Devlin AM, et al., Metabolic interactions of alcohol and folate[J]. J Nutr, 2002, 132(8 Suppl):2367S-2372S.
[8]	Duthie SJ. Folic acid deficiency and cancer: mechanisms of DNA instability[J]. Br Med Bull, 1999, 55(3):578-592.
[9]	Freudenheim JL, Graham S, Marshall JR, et al. Folate intake and carcinogenesis of the colon and rectum[J]. Int J Epidemiol, 1991, 20(2):368-374.
[10]	David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome[J]. Nature, 2014, 505(7484):559-563.
[11]	Wu GD, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial enterotypes[J]. Science, 2011, 334(6052):105-108.
[12]	Krautkramer KA, Kreznar JH, Romano KA, et al. Diet-Microbiota Interactions Mediate Global Epigenetic Programming in Multiple Host Tissues[J]. Mol Cell, 2016, 64(5):982-992.
[13]	Albenberg LG, Wu GD. Diet and the intestinal microbiome: associations, functions, and implications for health and disease[J]. Gastroenterology, 2014, 146(6):1564-1572.
[14]	Feng Q, Liang S, Jia H, et al. Gut microbiome development along the colorectal adenoma-carcinoma sequence[J]. Nat Commun, 2015, 6:6528.
[15]	Sung JJ, Lau JY, Goh KL, et al. Increasing incidence of colorectal cancer in Asia: implications for screening[J]. Lancet Oncol, 2005, 6(11):871-876.
[16]	Ohtani N. Microbiome and cancer[J]. Semin Immunopathol, 2015, 37(1):65-72.
[17]	Zeng MY, Inohara N, and Nunez G.Mechanisms of inflammation-driven bacterial dysbiosis in the gut[J]. Mucosal Immunol, 2017, 10(1):18-26.
[18]	Shanahan F. The colonic microbiota and colonic disease[J]. Curr Gastroenterol Rep, 2012, 14(5):446-452.
[19]	Gagniere J, Raisch J, Veziant J, et al. Gut microbiota imbalance and colorectal cancer[J]. World J Gastroenterol, 2016, 22(2):501-518.
[20]	Ahn J, Sinha R, Pei Z, et al. Human gut microbiome and risk for colorectal cancer[J]. J Natl Cancer Inst, 2013, 105(24):1907-1911.
[21]	Sinha R, Ahn J, Sampson JN, et al. Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations[J]. PLoS One, 2016, 11(3):e0152126.
[22]	Kostic AD, Chun E, Robertson L, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment[J]. Cell Host Microbe, 2013, 14(2):207-215.
[23]	McCoy AN, Araujo-Perez F, Azcarate-Peril A, et al.Fusobacterium is associated with colorectal adenomas[J]. PLoS One, 2013, 8(1):e53653.
[24]	Zeller G, Tap J, Voigt AY, et al. Potential of fecal microbiota for early-stage detection of colorectal cancer[J]. Mol Syst Biol, 2014, 10:766.
[25]	Kohoutova D, Smajs D, Moravkova P, et al. Escherichia coli strains of phylogenetic group B2 and D and bacteriocin production are associated with advanced colorectal neoplasia[J]. BMC Infect Dis, 2014, 14:733.
[26]	Baxter NT, Koumpouras CC, Rogers MA, et al. DNA from fecal immunochemical test can replace stool for detection of colonic lesions using a microbiota-based model[J]. Microbiome, 2016, 4(1):59.
[27]	Hale VL, Chen J, Johnson S, et al. Shifts in the fecal microbiota associated with adenomatous polyps[J]. Cancer Epidemiol Biomarkers Prev, 2016.
[28]	Zackular JP, Rogers MA, Ruffin MTt, et al. The human gut microbiome as a screening tool for colorectal cancer[J]. Cancer Prev Res (Phila), 2014, 7(11):1112-1121.
[29]	Liang JQ, Chiu J, Chen Y, et al. Fecal Bacteria Act as Novel Biomarkers for Non-Invasive Diagnosis of Colorectal Cancer[J]. Clin Cancer Res, 2017, 26(1):85-94.
[30]	Ohigashi S, Sudo K, Kobayashi D, et al. Changes of the intestinal microbiota, short chain fatty acids, and fecal pH in patients with colorectal cancer[J]. Dig Dis Sci, 2013, 58(6):1717-1726.
[31]	Kelly DL, Lyon DE, Yoon SL, et al. The Microbiome and Cancer: Implications for Oncology Nursing Science[J]. Cancer Nurs, 2016, 39(3):E56-62.
[32]	Claudino WM, Quattrone A, Biganzoli L, et al. Metabolomics: available results, current research projects in breast cancer, and future applications[J]. J Clin Oncol, 2007, 25(19):2840-2846.
[33]	Belcheva A, Irrazabal T, and Martin A. Gut microbial metabolism and colon cancer: can manipulations of the microbiota be useful in the management of gastrointestinal health?[J]. Bioessays, 2015, 37(4):403-412.
[34]	Herbert Tilg MD. A Gut Feeling about Thrombosis[J]. N Engl J Med, 2016, 23;374(25):2494-2496.
[35]	Xu R, Wang Q, and Li L. A genome-wide systems analysis reveals strong link between colorectal cancer and trimethylamine N-oxide (TMAO), a gut microbial metabolite of dietary meat and fat[J]. BMC Genomics, 2015, 16(Suppl 7):S4.
[36]	Lin Y, Ma C, Liu C, et al.NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer[J]. Oncotarget, 2016, 7(20):29454-29464.
[37]	Brown DG, Rao S, Weir TL, et al. Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool[J]. Cancer Metab, 2016, 4:11.
[38]	Goedert JJ, Sampson JN, Moore SC, et al. Fecal metabolomics: assay performance and association with colorectal cancer[J]. Carcinogenesis, 2014, 35(9):2089-2096.
[39]	Phua LC, Koh PK, Cheah PY, et al. Global gas chromatography/time-of-flight mass spectrometry (GC/TOFMS)-based metabonomic profiling of lyophilized human feces[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2013, 937:103-113.
[40]	Metallo CM. Expanding the reach of cancer metabolomics[J]. Cancer Prev Res (Phila), 2012, 5(12):1337-1340.
[41]	Monleon D, Morales JM, Barrasa A, et al. Metabolite profiling of fecal water extracts from human colorectal cancer[J]. NMR Biomed, 2009, 22(3):342-348.
[42]	Qiu Y, Cai G, Su M, et al. Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS[J]. J Proteome Res, 2009, 8(10):4844-4850.
[43]	Tan B, Qiu Y, Zou X, et al. Metabonomics identifies serum metabolite markers of colorectal cancer[J]. J Proteome Res, 2013, 12(6):3000-3009.
[44]	Kuhn T, Floegel A, Sookthai D, et al. Higher plasma levels of lysophosphatidylcholine 18: 0 are related to a lower risk of common cancers in a prospective metabolomics study[J]. BMC Med, 2016, 14:13.
[45]	Ritchie SA, Ahiahonu PW, Jayasinghe D, et al. Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection[J]. BMC Med, 2010, 8:13.
[46]	Farshidfar F, Weljie AM, Kopciuk KA, et al. A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics[J]. Br J Cancer, 2016, 115(7):848-857.
[47]	Zhu J, Djukovic D, Deng L, et al. Targeted serum metabolite profiling and sequential metabolite ratio analysis for colorectal cancer progression monitoring[J]. Anal Bioanal Chem, 2015, 407(26):7857-7863.
[48]	Ma Y, Zhang P, Wang F, et al.An integrated proteomics and metabolomics approach for defining oncofetal biomarkers in the colorectal cancer[J]. Ann Surg, 2012, 255(4):720-730.
[49]	Uchiyama K, Yagi N, Mizushima K, et al. Serum metabolomics analysis for early detection of colorectal cancer[J]. J Gastroenterol, 2017, 52(6):677-694.
[50]	Bertini I, Cacciatore S, Jensen BV, et al. Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer[J]. Cancer Res, 2012, 72(1):356-364.
[51]	Ritchie SA, Tonita J, Alvi R, et al. Low-serum GTA-446 anti-inflammatory fatty acid levels as a new risk factor for colon cancer[J]. Int J Cancer, 2013, 132(2):355-362.
[52]	Baxter NT, Ruffin MTt, Rogers MA, et al. Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions[J]. Genome Med, 2016, 8(1):37.
[53]	Watt E, Gemmell MR, Berry S, et al.Extending colonic mucosal microbiome analysis-assessment of colonic lavage as a proxy for endoscopic colonic biopsies[J]. Microbiome, 2016, 4(1):61.

研究者	年份	CRC患者数	健康对照数	样本类型	分析平台	结直肠癌中升高	结直肠癌中下降	参考文献
Farshidfar, F.	2016	320	254	血清	GC-MS	3-羟基丁酸、2-羟基丁酸、乙二醇、乳酸、硬脂酸、苯基丙氨酸、异亮氨酸、柠檬酸、赖氨酸、甘氨酸	苏糖酸、胱氨酸、树胶醛糖、丙二酸、壬烷、甘油	[46]
Kuhn, T.	2016	163	774	血清	liquid FIA-MS/MS和LC-MS/MS	磷脂胆碱	甘氨酸、丝氨酸、溶血磷脂胆碱	[44]
Uchiyama, K.	2016	56	60	血清	CE-TOFMS	3-羟基丁酸	异戊酸、鸟氨酸、苯甲酸、组氨酸、赖氨酸、色氨酸	[49]
Zhu, J.	2015	20	-	血清	LC-MS/MS	琥珀酸、N2，N2-二甲基鸟苷、腺嘌呤、柠康酸、1-甲基鸟苷	/	[47]
Tan, B.	2013	101	102	血清	GC-TOFMS和UPLC-QTOFMS	3-羟基丁酸、2-酮丁酸、四氢孕三烯酮	5-羟色胺、色氨酸、延胡索酸盐、吲哚丙烯酸、溶血磷脂酰胆碱	[43]
Ma, Y.	2012	30	-	血清	GC-MS	3-羟基丁酸	缬氨酸、苏氨酸、脱氧葡萄糖、甘氨酸、核糖醇	[48]
Bertini, I.	2012	153	139	血清	1H-NMR	3-羟基丁酸乙酯、甲酸、乙酸、甘油、苯丙氨酸、脯氨酸、脂质、糖蛋白	乳酸、丙酮酸、柠檬酸、丙氨酸、酪氨酸、缬氨酸、肌酸、谷氨酰胺	[50]
Ritchie, S. A.	2010	222	220	血清	FTICR-MS, LC-MS, NMR	/	羟基化多不饱和超长链脂肪酸	[51]
Qiu, Y.	2009	64	65	血清	GC-TOFMS和UPLC-QTOFMS	丙酮酸盐和乳酸	酪氨酸、色氨酸、尿苷	[42]
Lin, Y.	2016	68	32	粪便	1H-NMR	琥珀酸盐、脯氨酸、丙氨酸、二甲基甘氨酸、缬氨酸、谷氨酸、亮氨酸、异亮氨酸、乳酸	乙酸盐、丁酸盐、丙酸盐、葡萄糖、谷氨酰胺	[36]
Brown, D. G.	2016	13	-	粪便	GC-MS和UPLC-MS/MS	同量异位素：甜菜碱醛、N-甲基二乙醇胺、腺苷酸琥珀酸盐	葡萄糖-6-磷酸、果糖-6-磷酸	[37]
Goedert, J. J.	2014	48	102	粪便	HPLC-GC/MS-MS	对羟基苯甲醛、扁桃酸盐、棕榈酰鞘磷脂	对氨基苯甲酸、二氢谷甾醇、蝶呤、α-生育酚、γ-生育酚、脱氢肉碱、N-2-糠酰-甘氨酸、亚油酸盐	[38]
Phua, L. C.	2013	11	10	粪便	GC/TOFMS	/	烟酸、果糖、亚油酸	[39]
Monleon, D.	2009	21	11	粪便	NMR	亮氨酸、脯氨酸、半胱氨酸	乙酸盐、丁酸盐	[41]

研究者	年份	CRC患者数	健康对照数	样本类型	分析平台	结直肠癌中升高	结直肠癌中下降	参考文献
Farshidfar, F.	2016	320	254	血清	GC-MS	3-羟基丁酸、2-羟基丁酸、乙二醇、乳酸、硬脂酸、苯基丙氨酸、异亮氨酸、柠檬酸、赖氨酸、甘氨酸	苏糖酸、胱氨酸、树胶醛糖、丙二酸、壬烷、甘油	[46]
Kuhn, T.	2016	163	774	血清	liquid FIA-MS/MS和LC-MS/MS	磷脂胆碱	甘氨酸、丝氨酸、溶血磷脂胆碱	[44]
Uchiyama, K.	2016	56	60	血清	CE-TOFMS	3-羟基丁酸	异戊酸、鸟氨酸、苯甲酸、组氨酸、赖氨酸、色氨酸	[49]
Zhu, J.	2015	20	-	血清	LC-MS/MS	琥珀酸、N2，N2-二甲基鸟苷、腺嘌呤、柠康酸、1-甲基鸟苷	/	[47]
Tan, B.	2013	101	102	血清	GC-TOFMS和UPLC-QTOFMS	3-羟基丁酸、2-酮丁酸、四氢孕三烯酮	5-羟色胺、色氨酸、延胡索酸盐、吲哚丙烯酸、溶血磷脂酰胆碱	[43]
Ma, Y.	2012	30	-	血清	GC-MS	3-羟基丁酸	缬氨酸、苏氨酸、脱氧葡萄糖、甘氨酸、核糖醇	[48]
Bertini, I.	2012	153	139	血清	1H-NMR	3-羟基丁酸乙酯、甲酸、乙酸、甘油、苯丙氨酸、脯氨酸、脂质、糖蛋白	乳酸、丙酮酸、柠檬酸、丙氨酸、酪氨酸、缬氨酸、肌酸、谷氨酰胺	[50]
Ritchie, S. A.	2010	222	220	血清	FTICR-MS, LC-MS, NMR	/	羟基化多不饱和超长链脂肪酸	[51]
Qiu, Y.	2009	64	65	血清	GC-TOFMS和UPLC-QTOFMS	丙酮酸盐和乳酸	酪氨酸、色氨酸、尿苷	[42]
Lin, Y.	2016	68	32	粪便	1H-NMR	琥珀酸盐、脯氨酸、丙氨酸、二甲基甘氨酸、缬氨酸、谷氨酸、亮氨酸、异亮氨酸、乳酸	乙酸盐、丁酸盐、丙酸盐、葡萄糖、谷氨酰胺	[36]
Brown, D. G.	2016	13	-	粪便	GC-MS和UPLC-MS/MS	同量异位素：甜菜碱醛、N-甲基二乙醇胺、腺苷酸琥珀酸盐	葡萄糖-6-磷酸、果糖-6-磷酸	[37]
Goedert, J. J.	2014	48	102	粪便	HPLC-GC/MS-MS	对羟基苯甲醛、扁桃酸盐、棕榈酰鞘磷脂	对氨基苯甲酸、二氢谷甾醇、蝶呤、α-生育酚、γ-生育酚、脱氢肉碱、N-2-糠酰-甘氨酸、亚油酸盐	[38]
Phua, L. C.	2013	11	10	粪便	GC/TOFMS	/	烟酸、果糖、亚油酸	[39]
Monleon, D.	2009	21	11	粪便	NMR	亮氨酸、脯氨酸、半胱氨酸	乙酸盐、丁酸盐	[41]

Please choose a citation manager

Content to export